Indeed, oral administration of the PAI-1 inhibitor TM5275 effectively attenuates adenoviral-delivered TGF-β1 - induced pulmonary fibrosis, stimulated myofibroblast apoptosis and suppressed TGF-β1 -mediated expression of specific pro-fibrotic genes (e.g., fibronectin, PAI-1) [5]. Here, TGFB1 is linked to pulmonary fibrosis.